Shockwave Medical (NSDQ:SWAV) this week announced it signed an agreement to acquire all of the issued and outstanding common shares of Neovasc (NSDQ:NVCN). Neovasc enrolled its first patient in a clinical trial studying the Neovasc Reducer in January 2022. The company designed the device to reduce angina symptoms in people with refractory … [Read more...] about Shockwave Medical to acquire Neovasc for up to $147M